Charles River Laboratories Intl. Inc vs GE Aerospace — how do they compare? Charles River Laboratories Intl. Inc trades at $301.79 (market cap $14.23B), while GE Aerospace trades at $308.2 (market cap $317.10B). The key difference: GE Aerospace is far larger — about 22.3× Charles River Laboratories Intl. Inc's market cap, and GE Aerospace pays a 0.62% dividend while Charles River Laboratories Intl. Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Charles River Laboratories Intl. Inc for 33 Days and GE Aerospace for 111 Days on average.
| CRL | GE | |
|---|---|---|
Market Cap | $14.23B | $317.10B |
Volume | 1,176,885 | 6,320,106 |
Sector | Health | Industrials |
52-Week High | $310.77 | $381.22 |
52-Week Low | $149.93 | $273.25 |
Typical Hold Time | 33 Days | 111 Days |
Enterprise Value | $17.06B | $326.91B |
Dividend Yield | — | 0.62% |
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $298, down 0.77% on the day, with strong analyst support showing 73% buy ratings and a $305.50 consensus price target. The stock maintains a bullish technical outlook with support at $292 and resistance at $301, while recent earnings have consistently beaten expectations despite negative net income margins. The company's 2026 Investor Day highlighted a strategic vision targeting 5-7% organic growth and $300 million in savings by 2030.
CRL presents a compelling growth story with solid operational cash flow and strategic initiatives, though investors face risks from negative profitability metrics and elevated valuation multiples. The stock's current position near analyst targets suggests limited upside without improved earnings execution, while ongoing margin pressures and debt levels require careful monitoring amid the company's transformation efforts.
GE Aerospace (GE) trades at $305.62, up 0.66% on the day, but faces a near-term bearish technical signal despite strong fundamentals. The company reported robust earnings beats in recent quarters, with Q2 2026 EPS of $2.02 exceeding the $1.86 estimate. Revenue growth is accelerating, reaching $45.86 billion in 2025, while net income margins improved to 17.72%. However, the stock's high valuation multiples, including a P/E of 36.04, and a significant $12 billion acquisition of Consolidated Precision Products, present both opportunity and scrutiny.
The outlook remains positive driven by strong defense demand and shareholder returns, including a $20 billion buyback and raised dividend. Analyst consensus is strongly bullish with a $409.60 price target, though risks include integration challenges from the CPP deal, cost pressures, and high debt levels. The stock's current price is approximately 25% below the consensus target, suggesting potential upside if execution risks are managed.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →General Electric Company is a globally diversified technology and financial services company. The Company's products and services include aircraft engines, power generation, water processing, and household appliances to medical imaging, business and consumer financing, and industrial products.
Read more on GE →